Epclusa (sofosbuvir and velpatasvir)
What is the dosage for Epclusa?
According to Gilead, developer of Epclusa, one tablet should be taken once daily with or without food. For patients with genotypes 1, 2, 3, 4, 5, or 6 HCV, the regimen and duration is below:
|Patient Population||Recommended Duration of Treatment|
|Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A)||
Epclusa for 12 weeks
|Patients with decompensated cirrhosis (Child-Pugh B and C)||
Epclusa with ribavirin for 12 weeks
For those with severe renal impairment and end stage renal disease, no dose recommendation for Epclusa can be given due to higher exposures of the predominant sofosbuvir metabolite.
You should take Epclusa once a day on a regular dosing schedule with or without food. It is important not to miss or skip doses and to continue taking it for the duration recommended by your physician.
Last Updated: June 2016
"Co-pay Coupon | EPCLUSA®." Gilead.com. Gilead Sciences, Inc., https://www.epclusainfo.com/co-pay-coupon-registration. Retrieved June 29, 2016
"Highlights of Prescribing Information." FDA.gov. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf. Retrieved June 29, 2016.
"Support Path Harvoni® and Epclusa® Tablets Treatment Support." Gilead.com. Gilead Sciences, Inc., http://www.mysupportpath.com/. Retrieved June 29, 2016.
"U.S. Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C. Gilead.com". http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&. Retrieved June 29, 2016.